Completed PHASE4 INTERVENTIONAL NCT00319189

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance

Sponsor: University of Oslo School of Pharmacy

Conditions Posttransplant Diabetes Mellitus Posttransplant Impaired Glucose Tolerance Renal Transplant Recipients

Interventions Nateglinide

Updated 5 times since 2017 Last updated: May 9, 2006 Started: Nov 30, 2002 Completion: Nov 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Posttransplant Diabetes Mellitus and Posttransplant Impaired Glucose Tolerance, this trial is completed. The trial is conducted by University of Oslo School of Pharmacy and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Oslo School of Pharmacy

Data source: University of Oslo School of Pharmacy

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway